A systematic review and meta-analysis in PubMed pooled safety data on second primary malignant neoplasms after T-cell-engaging bispecific antibody therapy in adults with B-cell non-Hodgkin lymphoma or multiple myeloma. Across 26 cohorts (2,551 patients) the authors estimated a pooled total SPM frequency of 3.5% at a median follow-up of 17.4 months, with separate estimates for treatment-discontinuation and death outcomes.